Douglas L. Huseby, Ph.D.
Affiliations: | 2012 | Biochemistry and Molecular Biology | University of California, Davis, Davis, CA |
Area:
Microbiology BiologyGoogle:
"Douglas Huseby"Parents
Sign in to add mentorJohn Roger Roth | grad student | 2012 | UC Davis | |
(Function of microcompartments in the metabolism of ethanolamine in Salmonella enterica.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Praski Alzrigat L, Huseby DL, Brandis G, et al. (2020) Resistance/fitness trade-off is a barrier to the evolution of MarR inactivation mutants in Escherichia coli. The Journal of Antimicrobial Chemotherapy |
Garoff L, Pietsch F, Huseby DL, et al. (2020) Population bottlenecks strongly influence the evolutionary trajectory to fluoroquinolone resistance in Escherichia coli. Molecular Biology and Evolution |
Huseby DL, Brandis G, Praski Alzrigat L, et al. (2020) Antibiotic resistance by high-level intrinsic suppression of a frameshift mutation in an essential gene. Proceedings of the National Academy of Sciences of the United States of America |
Juhas M, Widlake E, Teo J, et al. (2019) In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii. The Journal of Antimicrobial Chemotherapy |
Vestö K, Huseby DL, Snygg I, et al. (2018) Muramyl Endopeptidase Spr Contributes to Intrinsic Vancomycin Resistance in Serovar Typhimurium. Frontiers in Microbiology. 9: 2941 |
Garoff L, Huseby DL, Praski Alzrigat L, et al. (2018) Effect of aminoacyl-tRNA synthetase mutations on susceptibility to ciprofloxacin in Escherichia coli. The Journal of Antimicrobial Chemotherapy |
Pantel L, Florin T, Dobosz-Bartoszek M, et al. (2018) Odilorhabdins, Antibacterial Agents that Cause Miscoding by Binding at a New Ribosomal Site. Molecular Cell. 70: 83-94.e7 |
Jeannot F, Taillier T, Despeyroux P, et al. (2018) Imidazopyrazinones (IPYs): non-quinolone bacterial topoisomerase inhibitors showing partial cross-resistance with quinolones. Journal of Medicinal Chemistry |
Huseby DL, Hughes D. (2018) Methods to Determine Mutational Trajectories After Experimental Evolution of Antibiotic Resistance. Methods in Molecular Biology (Clifton, N.J.). 1736: 95-103 |
Praski Alzrigat L, Huseby DL, Brandis G, et al. (2017) Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli. The Journal of Antimicrobial Chemotherapy |